FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Vet Intern Med / Randomized, controlled trial comparing Rhodococcus equi and ...
Journal of veterinary internal medicine2021; 35(6); 2912-2919; doi: 10.1111/jvim.16294

Randomized, controlled trial comparing Rhodococcus equi and poly-N-acetyl glucosamine hyperimmune plasma to prevent R equi pneumonia in foals.

Abstract: Hyperimmune plasma raised against β-1→6-poly-N-acetyl glucosamine (PNAG HIP) mediates more opsonophagocytic killing of Rhodococcus equi (R equi) than does R equi hyperimmune plasma (RE HIP) in vitro. The relative efficacy of PNAG HIP and RE HIP to protect foals against R equi pneumonia, however, has not been evaluated. Objective: Transfusion with PNAG HIP will be superior to RE HIP in foals for protection against R equi pneumonia in a randomized, controlled, blinded clinical trial. Methods: Four hundred sixty Quarter Horse and Thoroughbred foals at 5 large breeding farms in the United States. Methods: A randomized, controlled, blinded clinical trial was conducted in which foals were transfused within 24 hours after birth with 2 L of either RE HIP or PNAG HIP. Study foals were monitored through weaning for clinical signs of pneumonia by farm veterinarians. The primary outcome was the proportion of foals that developed pneumonia after receiving each type of plasma. Results: The proportion of foals that developed pneumonia was the same between foals transfused with RE HIP (14%; 32/228) and PNAG HIP (14%; 30/215). Conclusions: Results indicate that PNAG HIP was not superior to a commercially available, United States Department of Agriculture-licensed RE HIP product for protecting foals against R equi pneumonia under field conditions.
© 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2021-11-05 PubMed ID: 34738651PubMed Central: PMC8692225DOI: 10.1111/jvim.16294Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Randomized Controlled Trial
  • Veterinary

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article is discussing the relative effectiveness of two different types of hyperimmune plasma, Rhodococcus equi hyperimmune plasma (RE HIP) and poly-N-acetyl glucosamine hyperimmune plasma (PNAG HIP), in protecting foals against bacterial pneumonia caused by Rhodococcus equi.

Objective of the Study

  • The main objective of the study was to evaluate whether transfusions of PNAG HIP would be more effective in protecting foals against Rhodococcus equi pneumonia than RE HIP. This evaluation was done through a randomized, controlled, and blinded clinical trial.

Methods Used

  • The trial included 460 Quarter Horse and Thoroughbred foals from 5 large breeding farms in the United States.
  • Within 24 hours after birth, the foals were transfused with 2 litres of either RE HIP or PNAG HIP.
  • The foals were monitored through weaning for clinical signs of pneumonia by farm veterinarians. The main outcome the researchers were observing was the proportion of foals that developed pneumonia after receiving each type of plasma.

Results of the Study

  • The results demonstrated that the proportion of foals that developed pneumonia was the same for both groups. 14% of foals (or 32 out of 228) that received RE HIP developed pneumonia, and the same percentage (or 30 out of 215 foals) that received PNAG HIP also developed the condition.

Conclusions of the Study

  • Based on these results, the researchers concluded that PNAG HIP is not superior to a commercially available, RE HIP product licensed by the United States Department of Agriculture (USDA) in protecting foals against Rhodococcus equi pneumonia under field conditions. This means that the existing treatment method using RE HIP remains as effective as the new treatment method using PNAG HIP, and therefore no change in clinical practice is warranted based on this trial’s results.

Cite This Article

APA
Kahn SK, Cywes-Bentley C, Blodgett GP, Canaday NM, Turner-Garcia CE, Flores-Ahlschwede P, Metcalfe LL, Nevill M, Vinacur M, Sutter PJ, Meyer SC, Bordin AI, Pier GB, Cohen ND. (2021). Randomized, controlled trial comparing Rhodococcus equi and poly-N-acetyl glucosamine hyperimmune plasma to prevent R equi pneumonia in foals. J Vet Intern Med, 35(6), 2912-2919. https://doi.org/10.1111/jvim.16294

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 35
Issue: 6
Pages: 2912-2919

Researcher Affiliations

Kahn, Susanne K
  • Equine Infectious Disease Laboratory, Department of Large Animal Clinical Sciences, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
Cywes-Bentley, Colette
  • Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Blodgett, Glenn P
  • 6666 Ranch, Guthrie, Texas, USA.
Canaday, Nathan M
  • 6666 Ranch, Guthrie, Texas, USA.
Turner-Garcia, Carly E
  • Lazy E Ranch, Guthrie, Oklahoma, USA.
Flores-Ahlschwede, Patricia
  • Rood & Riddle Equine Hospital in Saratoga, Saratoga Springs, New York, USA.
Metcalfe, Laurie L
  • Rood & Riddle Equine Hospital, Lexington, Kentucky, USA.
Nevill, Mark
  • Granada Farms, Wheelock, Texas, USA.
Vinacur, Mariana
  • Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Sutter, Patrick J
  • Mg Biologics, Inc, Ames, Iowa, USA.
Meyer, Sarah C
  • Mg Biologics, Inc, Ames, Iowa, USA.
Bordin, Angela I
  • Equine Infectious Disease Laboratory, Department of Large Animal Clinical Sciences, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
Pier, Gerald B
  • Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Cohen, Noah D
  • Equine Infectious Disease Laboratory, Department of Large Animal Clinical Sciences, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.

MeSH Terms

  • Acetylglucosamine
  • Actinomycetales Infections / prevention & control
  • Actinomycetales Infections / veterinary
  • Animals
  • Antibodies, Bacterial
  • Horse Diseases / prevention & control
  • Horses
  • Pneumonia, Bacterial / prevention & control
  • Pneumonia, Bacterial / veterinary
  • Rhodococcus equi

Grant Funding

  • Grayson-Jockey Club Research Foundation
  • Link Equine Research Endowment, Equine Infectious Disease Epidemiology Program

Conflict of Interest Statement

Gerald B. Pier is an inventor of intellectual properties (human monoclonal antibody to PNAG and PNAG vaccines) that are licensed by Brigham and Women\'s Hospital to Alopexx Inc, an entity in which Gerald B. Pier also holds equity. As an inventor of intellectual properties, Gerald B. Pier also has the right to receive a share of licensing‐related income (royalties, fees) through Brigham and Women\'s Hospital from Alopexx Inc. Gerald B. Pier\'s interests were reviewed and are managed by the Brigham and Women\'s Hospital and Partners Health care in accordance with their conflict of interest policies. Colette Cywes‐Bentley is an inventor of intellectual properties (use of human monoclonal antibody to PNAG and use of PNAG vaccines) that are licensed by Brigham and Women\'s Hospital to Alopexx Inc. As an inventor of intellectual properties, Colette Cywes‐Bentley also has the right to receive a share of licensing‐related income (royalties, fees) through Brigham and Women\'s Hospital from Alopexx Inc. Sarah C. Meyer and Patrick J. Sutter work for MG Biologics that produced the plasma used for this project and thus might have potential earnings from plasma sales, but they had no part in the study design other than masking plasma and did not participate in data analysis. No other authors have a conflict of interest.

References

This article includes 35 references
  1. Cohen ND. Rhodococcus equi foal pneumonia.. Vet Clin North Am Equine Pract 2014;30(3):609‐622.
    pubmed: 25282322
  2. Giguere S, Cohen ND, Chaffin MK. Rhodococcus equi: clinical manifestations, virulence, and immunity.. J Vet Intern Med 2011;2S:1221‐1230.
    pubmed: 22092609
  3. Prescott JF. Rhodococcus equi: an animal and human pathogen.. Clin Microbiol Rev 1991;4:20‐34.
    pmc: PMC358176pubmed: 2004346
  4. Cohen ND, O'Conor MS, Chaffin MK. Farm characteristics and management practices associated with Rhodococcus equi pneumonia in foals.. J Am Vet Med Assoc 2005;226:404‐413.
    pubmed: 15702691
  5. Chaffin MK, Cohen ND, Martens RJ. Chemoprophylactic effects of azithromycin against Rhodococcus equi‐induced pneumonia among foals at equine breeding farms with endemic infections.. J Am Vet Med Assoc 2008;232:1035‐1047.
    pubmed: 18380623
  6. Chaffin MK, Cohen ND, Martens RJ, O'Conor M, Bernstein LR. Evaluation of the efficacy of gallium maltolate for chemoprophylaxis against pneumonia caused by Rhodococcus equi infection in foals.. Am J Vet Res 2011;72:945‐957.
    pubmed: 21728856
  7. Coleman MC, Blodgett GP, Bevevino KE. Foal‐level risk factors associated with development of Rhodococcus equi pneumonia at a Quarter Horse breeding farm.. J Equine Vet Sci 2019;72:89‐96.
    pubmed: 30929790
  8. Arnold‐Lehna D, Venner M, Berghaus LJ, Berghaus R, Giguère S. Changing policy to treat foals with Rhodococcus equi pneumonia in the later course of disease decreases antimicrobial usage without increasing mortality rate.. Equine Vet J 2020;52:531‐537.
    pubmed: 31808183
  9. Ainsworth DM, Eicker SW, Yeager AE. Associations between physical examination, laboratory, and radiographic findings and outcome and subsequent racing performance of foals with Rhodococcus equi infection: 11S cases (1984‐1992).. J Am Vet Med Assoc 1998;213:510‐515.
    pubmed: 9713534
  10. Chaffin MK, Cohen ND, Martens RJ. Chemoprophylactic effects of azithromycin against Rhodococcus equi‐induced pneumonia among foals at equine breeding farms.. J Am Vet Med Assoc 2008;232:1035‐1047.
    pubmed: 18380623
  11. Martens RJ, Martens JG, Fiske RA. Rhodococcus equi foal pneumonia: protective effects of immune plasma in experimentally infected foals.. Equine Vet J 1989;21:249‐255.
    pubmed: 2767025
  12. Madigan JE, Hietala S, Muller N. Protection against naturally acquired Rhodococcus equi pneumonia in foals by administration of hyperimmune plasma.. J Reprod Fertil Suppl 1991;44:571‐578.
    pubmed: 1795301
  13. Giguere S, Gaskin JM, Miller C, Bowman JL. Evaluation of a commercially available hyperimmune plasma product for prevention of pneumonia caused by Rhodococcus equi in foals.. J Am Vet Med Assoc 2002;220:59‐63.
    pubmed: 12680449
  14. Venner M, Reinhold B, Beyerbach M, Feige K. Efficacy of azithromycin in preventing pulmonary abscesses in foals.. Vet J 2009;179:301‐303.
    pubmed: 18023599
  15. Higuchi T, Arakawa T, Hashikura S. Effect of prophylactic administration of hyperimmune plasma to prevent R. equi infection on foals from endemically affected farms.. Zentralbl Veterinarmed B 1999;46:641‐648.
    pubmed: 10605374
  16. Martens RJ, Martens JG, Fiske RA. Failure of passive immunisation by colostrum from immunised mares to protect foals against R. equi pneumonia.. Equine Vet J Suppl 1991;12:19‐22.
  17. Varga J, Fodor L, Rusvai M. Prevention of Rhodococcus equi pneumonia of foals using two different inactivated vaccines.. Vet Microbiol 1997;56:205‐212.
    pubmed: 9226835
  18. Becu T, Polledo G, Gaskin JM. Immunoprophylaxis of Rhodococcus equi pneumonia in foals.. Vet Microbiol 1997;56:193‐204.
    pubmed: 9226834
  19. Cauchard J, Sevin C, Ballet J. Foal IgG and opsonising anti‐R. equi antibodies after immunisation of pregnant mares with a protective VapA candidate vaccine.. Vet Microbiol 2004;104:73‐81.
    pubmed: 15530741
  20. Takai S, Kobayashi C, Murakami K, Sasaki Y, Tsubaki S. Live virulent R. equi, rather than killed or avirulent, elicits protective immunity to R. equi in mice.. FEMS Immunol Med Microbiol 1999;24:1‐9.
    pubmed: 10340706
  21. Prescott JF, Nicholson VM, Patterson MC. Use of Rhodococcus equi virulence‐associated protein for immunization of foals against R. equi pneumonia.. Am J Vet Res 1997;58:344‐349.
    pubmed: 9099378
  22. Lopez AM, Hines MT, Palmer GH, Knowles DP, Alperin DC, Hines SA. Analysis of anamnestic immune responses in adult horses and priming in neonates induced by a DNA vaccine expressing the vapA gene of Rhodococcus equi .. Vaccine 2003;21:3815‐3825.
    pubmed: 12922115
  23. Mealey RH, Stone DM, Hines MT. Experimental Rhodococcus equi and equine infectious anemia virus DNA vaccination in adult and neonatal horses: effect of IL‐12, dose, and route.. Vaccine 2007;25:7582‐7597.
    pmc: PMC3342688pubmed: 17889970
  24. Lopez AM, Townsend HG, Allen AL. Safety and immunogenicity of a live‐attenuated auxotrophic candidate vaccine against the intracellular pathogen Rhodococcus equi .. Vaccine 2008;13:998‐1009.
    pubmed: 18055071
  25. Pei Y, Nicholson V, Woods K, Prescott JF. Immunization by intrabronchial administration to 1‐week‐old foals of an unmarked double gene disruption strain of Rhodococcus equi strain 103+.. Vet Microbiol 2007;125:100‐110.
    pubmed: 17560744
  26. Rocha JN, Cohen ND, Bordin AI. Oral administration of electron‐beam inactivated Rhodococcus equi failed to protect foals against intrabronchial infection with live, virulent R. equi .. PLoS One 2016;11(2):e0148111.
    pmc: PMC4735123pubmed: 26828865
  27. Hurley JR, Begg AP. Failure of hyperimmune plasma to prevent pneumonia caused by Rhodococcus equi in foals.. Aust Vet J 1995;72:418‐420.
    pubmed: 8929188
  28. Cywes‐Bentley C, Rocha JN, Bordin AI. Antibody to poly‐N‐acetyl glucosamine provides protection against intracellular pathogens: mechanism of action and validation in horse foals challenged with Rhodococcus equi .. PLoS Pathog 2018;14(7):e1007160.
    pmc: PMC6053243pubmed: 30024986
  29. Kahn SK, Blodgett GP, Canaday NM. Transfusion with 2 liters of hyperimmune plasma is superior to transfusion of 1 liter or less for protecting foals against sub‐clinical pneumonia attributed to Rhodococcus equi .. J Equine Vet Sci 2019;79:54‐58.
    pubmed: 31405501
  30. Flores‐Ahlschwede P, Kahn SK, Ahlschwede S, Bordin AI, Cohen ND. Transfusion with 2 liters of hyperimmune plasma is superior to transfusion of 1 liter for protecting foals against pneumonia attributed to Rhodococcus equi .. Equine Vet Educ 2021.
    doi: 10.1111/eve.13443pubmed: 0google scholar: lookup
  31. Sanz MG, Loynachan A, Horohov DW. Rhodococcus equi hyperimmune plasma decreases pneumonia severity after a randomized experimental challenge of neonatal foals.. Vet Rec 2016;178:261.
    pubmed: 26932206
  32. Sanz MG, Oliveira AF, Page A, Horohov DW. Administration of commercial Rhodococcus equi specific hyperimmune plasma results in variable amounts of IgG against pathogenic bacteria.. Vet Rec 2016;175:485.
    pubmed: 25117301
  33. Rakowska A, Cywinska A, Witkowski L. Current trends in understanding and managing equine rhodococcosis.. Animals 2020;10(10):1910.
    pmc: PMC7603097pubmed: 33081047
  34. Folmar CN, Cywes‐Bentley C, Bordin AI. In vitro evaluation of complement deposition and opsonophagocytic killing of Rhodococcus equi mediated by poly‐N‐acetyl glucosamine hyperimmune plasma compared to commercial plasma products.. J Vet Intern Med 2019;33(3):1493‐1499.
    pmc: PMC6524092pubmed: 31034109
  35. Cywes‐Bentley C, Skurnik D, Zaidi T. Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens.. Proc Natl Acad Sci U S A 2013;110(24):e2209‐e2218.
    pmc: PMC3683766pubmed: 23716675
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.